NASDAQ:ENTA

Enanta Pharmaceuticals Stock Forecast, Price & News

$41.30
-0.70 (-1.67 %)
(As of 07/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$41.02
$42.30
50-Day Range
$41.02
$49.57
52-Week Range
$40.32
$56.97
Volume136,287 shs
Average Volume143,248 shs
Market Capitalization$834.05 million
P/E RatioN/A
Dividend YieldN/A
Beta0.39
30 days | 90 days | 365 days | Advanced Chart
Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Enanta Pharmaceuticals logo

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

1509th out of 4,434 stocks

Pharmaceutical Preparations Industry

731st out of 1,734 stocks

Analyst Opinion: 3.1Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

Is Enanta Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Enanta Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View analyst ratings for Enanta Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Enanta Pharmaceuticals?

Wall Street analysts have given Enanta Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Enanta Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Enanta Pharmaceuticals
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.15. The biotechnology company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $25.05 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 12.21% and a negative net margin of 78.57%. The company's quarterly revenue was down 27.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share.
View Enanta Pharmaceuticals' earnings history
.

How has Enanta Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ENTA stock has decreased by 22.0% and is now trading at $41.30.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ENTA?

7 brokers have issued 12 month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $30.00 to $107.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $65.29 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 65, Pay $1.1M)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 66, Pay $612.52k)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 69, Pay $675.48k)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 67, Pay $619.67k)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 55, Pay $644.09k)
  • Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. Communications
  • Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 43)
  • Mr. Brendan Luu, Sr. VP of Bus. Devel.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Enanta Pharmaceuticals' key competitors?

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%).
View institutional ownership trends for Enanta Pharmaceuticals
.

Which institutional investors are buying Enanta Pharmaceuticals stock?

ENTA stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Enanta Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $41.30.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals has a market capitalization of $834.05 million and generates $122.47 million in revenue each year. The biotechnology company earns $-36,170,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 141 workers across the globe.

What is Enanta Pharmaceuticals' official website?

The official website for Enanta Pharmaceuticals is www.enanta.com.

Where are Enanta Pharmaceuticals' headquarters?

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.